A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients
Janet Rea Hardy, Susan M. Daly, B. McQuade et al. · Supportive Care in Cancer · 2002
Cited by 77 works. doi:10.1007/s00520-001-0332-1
Authors
- Janet Rea Hardy
- Susan M. Daly
- B. McQuade
- Martin Albertsson
- V. Chimontsi-Kypriou
- George P. Stathopoulos
- Paula S. Curtis
References
- Randomised trial of oral morphine for chronic non-cancer pain
- Prevention of Postoperative Nausea and Vomiting Using Ondansetron, a New, Selective, 5-HT3 Receptor Antagonist
- Cancer pain: management
- Barriers to Effective Cancer Pain Management
- What influences participation in clinical trials in palliative care in a cancer centre?
- Opioid Analgesic Therapy
- The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
- The incidence of narcotic-induced emesis
- Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
- Safety of ondansetron.